secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001437749-24-031300
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed completes last patient visit in Phase 2b DLB trial; topline data expected Dec 2024
--------------------------------------------------------------------------------

- Last patient last visit completed in Phase 2b RewinD-LB trial evaluating neflamapimod in early-stage DLB.
- 96% of patients completed the 16-week double-blind placebo-controlled portion; 98% continued into open-label extension.
- DSMB concluded study may proceed without modification after pre-specified safety data review.
- Company on track to report topline efficacy and safety data in December 2024.
- Late-breaking oral presentations on plasma biomarker data planned at upcoming CTAD conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924031300/0001437749-24-031300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924031300/crvo20241015_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer